Key result
Fixed-dose triple combination therapy achieved target 24-h ambulatory blood pressure in more patients than free-combination therapy at 4 months.
Why the study?
Does a fixed-dose triple combination of perindopril/indapamide/amlodipine improve blood pressure control compared to a free combination of three antihypertensives in patients with uncontrolled hypertension?
Does a fixed-dose triple combination of perindopril/indapamide/amlodipine improve blood pressure control compared to a free combination of three antihypertensives in patients with uncontrolled hypertension?
A fixed-dose triple combination of perindopril, indapamide, and amlodipine provides faster and more effective 24-hour blood pressure control compared to a free combination of similar agents in patients with uncontrolled hypertension.
Answers are grounded in this paper and cite their sources.
FDTC may improve BP control versus free combinations in uncontrolled hypertension; leaves open need for larger randomized trials before practice change.
INTRODUCTION: Blood pressure (BP) control is the main clinical goal in the management of hypertensive patients; however, BP in most of these patients remains uncontrolled, despite the widespread availability of antihypertensive drugs as free-combination therapy. This study compared the efficacy of a fixed-dose triple combination (FDTC) of antihypertensive drugs with that of a free combination of three antihypertensives in patients with uncontrolled hypertension. METHODS: Ninety-two patients (mean age 60.8 ± 12.1, 58.0% male) with uncontrolled essential hypertension (office systolic BP ≥ 140 or diastolic BP ≥ 90 mmHg) previously treated with a renin-angiotensin-aldosterone system (RAAS) inhibitor plus hydrochlorothiazide were switched to once-daily FDTC therapy with perindopril/indapamide/amlodipine (5-10/1.25-2.5/5-10 mg). Patients were age- and sex-matched with a control group of hypertensive patients receiving free-combination therapy with three drugs including a RAAS inhibitor, a diuretic, and a calcium channel blocker. Office BP and 24-h ambulatory BP monitoring (ABPM) were evaluated at baseline and after 1 and 4 months. RESULTS: Significant reductions in ambulatory 24-h, daytime, and nighttime systolic BP, and pulse pressure (PP) were found in the FDTC group relative to reductions seen with free-combination therapy, after the first month only of follow-up. Target BP values (mean 24-h ambulatory systolic/diastolic BP < 130/80 mmHg) were reached by more recipients of FDTC than free-combination therapy (64.8% vs. 46.9%, p < 0.05) at month 4 of follow-up, despite reductions in 24-h ABPM values from baseline being similar in both groups at this time point. CONCLUSION: FDTC of perindopril/indapamide/amlodipine was effective at reducing SBP and PP in previously treated patients with uncontrolled hypertension, and well tolerated, providing support for clinicians in choosing a fixed-dose triple combination over the free-combination of a RAAS inhibitor, a diuretic, and a calcium antagonist.
No takes yet. Share an insight, caveat, or question.
Mazza et al. (2017) studied Uncontrolled essential hypertension (n=184). Fixed-dose triple combination of perindopril/indapamide/amlodipine vs. Free-combination of three antihypertensives (RAAS blocker, diuretic, calcium channel blocker) was evaluated on Target 24-h ambulatory blood pressure (<130/80 mmHg) at 4 months (p=<0.05). Fixed-dose triple combination therapy achieved target 24-h ambulatory blood pressure in more patients than free-combination therapy at 4 months.
Synapse has enriched 10 related papers. Consider them for comparative context: